Cell Line Development Market Evolution By Recent Trends, Regional Growth, Revenue and Opportunities Till 2028 | Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection,

The Cell Line Development Market Is Growing With the Increasing Vaccine Production

Market Overview:

Cell line development is a clinical diagnostic technique used to examine the efficiency of drug discovery and toxicity. It is essential for recombinant protein production, such as bi-specific monoclonal antibodies, monoclonal antibodies, growth factors, and enzymes using a variety of expression systems. Cell line development can be used for in vitro testing and helps reduce the chances of drug to fail in clinical trial stage. It has reached new frontiers due to considerable genomic research and development activities. It is a major step for examining the efficiency of drug discovery, toxicity, and in vitro testing. It minimizes time, cost, and effort, which reduces the likelihood of research drug to fail in the clinical trial phase.

𝐓𝐨 𝐠𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.coherentmarketinsights.com/insight/request-sample/1286

Competitive Landscape:

Major players operating in the global cell line development market are Cleancells, Sartorious AG, Corning, Inc., GE Healthcare, Selexis SA, PX'Therapeutics SA., Lonza Group AG, Wuxi App Tec, Inc., Thermo Fisher Scientific, Inc., American Type Culture Collection, Goodwin Biotechnology Inc., Sigma-Aldrich Corporation, European Collection of Cell Cultures, among others.

Key Market Drivers:

Increasing prevalence of cancer and cancer therapeutics is expected to augment the growth of the cell line development market over the forecast period. For instance, according to the World Health Organization (WHO), cancer is one of the leading cause of death worldwide, accounting for around 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and prostate cancers.

Moreover, growing vaccine production due to increasing prevalence of life-threatening disease is expected to boost the growth of the cell line development market. For instance, according to International Federation of Pharmaceutical Manufacturers & Associations, COVID-19 vaccine production effort is estimated to reach 12.5 billion doses by the end of 2021 and double again to 24 billion doses by June 2022; supplies will most likely outstrip global demand.

COVID-19 Impact Analysis:

The outbreak of COVID-19 has prompted many pharmaceutical companies to develop vaccines and therapeutic biologics for its prevention and treatment. With the increasing prevalence of COVID-19, the demand for safe and effective vaccine or treatment is also increasing. This in turn is expected to increase the use of cell line development. According to WHO, as of 16 May 2022, a total of 12,186,798,032 vaccine doses have been administered.

𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/1286

Key Takeaways:

• The cell line development market is expected to exhibit during the forecast period due to the technological innovation in cell line development. For instance, in July 2021, Catalent launched next-generation cell-line development technology, named GPEx Lightning, which combines innovative technologies, including a novel gene insertion technology, to further shorten drug substance development by up to three months compared to previous timelines and can potentially save six to 12 weeks of development timelines.

• Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the cell line development market owing to the increasing prevalence of chronic disease, growing vaccine production, growing demand for monoclonal antibodies (mAbs), innovative technologies accelerating the scale-up of cell lines, and growing production of biosimilars due to the patent expiry of branded therapeutics.

• For instance, in October 2021, Cytena announced the launch of the C.Station platform for automating the development of stable cell lines. C.Station is a user-friendly platform that covers the entire cell line development workflow, from single-cell cloning of transfected cells to the selection of high-producing clones and up-scaling.

• Moreover, in August 2020, Samsung Biologics announced the launch of its proprietary cell line technology, S-CHOice. Samsung Biologics also signed a development contract with a client under which S-CHOice will be used to advance its cell line development.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅 @ https://www.coherentmarketinsights.com/promo/buynow/1286

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This release was published on openPR.